Female Sexual Dysfunction – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Female Sexual Dysfunction – Pipeline Review, H1 2020’, provides an overview of the Female Sexual Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction

– The report reviews pipeline therapeutics for Female Sexual Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Female Sexual Dysfunction therapeutics and enlists all their major and minor projects

– The report assesses Female Sexual Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Female Sexual Dysfunction

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Female Sexual Dysfunction pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Applied Biology Inc

Better Life Pharmaceuticals Inc

Callitas Therapeutics Inc

Can-Fite BioPharma Ltd

Dare Bioscience Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

H. Lundbeck AS

Harrow Health Inc

Ivix Ltd

Kuhnil Pharmaceutical Co Ltd

M et P Pharma AG

Re-Pharm Ltd

S1 Biopharma Inc

TherapeuticsMD Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Female Sexual Dysfunction - Overview

Female Sexual Dysfunction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Female Sexual Dysfunction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Sexual Dysfunction - Companies Involved in Therapeutics Development

Applied Biology Inc

Better Life Pharmaceuticals Inc

Callitas Therapeutics Inc

Can-Fite BioPharma Ltd

Dare Bioscience Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

H. Lundbeck AS

Harrow Health Inc

Ivix Ltd

Kuhnil Pharmaceutical Co Ltd

M et P Pharma AG

Re-Pharm Ltd

S1 Biopharma Inc

TherapeuticsMD Inc

Female Sexual Dysfunction - Drug Profiles

(buspirone hydrochloride + testosterone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(sildenafil citrate + testosterone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

estradiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FKW-00GA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Female Sexual Dysfunction - Dormant Projects

Female Sexual Dysfunction - Discontinued Products

Female Sexual Dysfunction - Product Development Milestones

Featured News & Press Releases

Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder

Dec 11, 2019: Daré Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder

Oct 30, 2019: Knight and TherapeuticsMD announce filing of new drug submission for Joyesta in Canada

Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildenafil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference

Oct 08, 2019: Mayfield Pharmaceuticals to Present update on lidocaine at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019

Sep 24, 2019: TherapeuticsMD announces multiple presentations related to IMVEXXY at the 2019 Annual Meeting of the North American Menopause Society

Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101

Jun 17, 2019: Daré Bioscience announces positive results in Thermography feasibility study with Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder

Apr 23, 2019: Ovoca Bio announced US and EU clinical development plans

Mar 25, 2019: Ovoca Bio Libicore (BP-101) meets primary/secondary endpoints in phase 3 trial for hypoactive sexual desire disorder ahead of time

Mar 18, 2019: Dare Bioscience to present update on Sildenafil Cream at 31st Annual ROTH Conference

Jan 04, 2019: S1 Biopharma announces expanded analysis of phase 2a data on Lorexys for treatment of hypoactive sexual desire disorder based on PGIC scale to be presented at 2019 ISSWSH/ISSM joint meeting

Dec 20, 2018: S1 Biopharma granted patents for Lorexys in Europe and Asia for treatment of hypoactive sexual desire disorder

Nov 29, 2018: Dare Bioscience announces initiation of content validity study for Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder

Nov 27, 2018: Dare Bioscience Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Female Sexual Dysfunction, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Female Sexual Dysfunction – Pipeline by Applied Biology Inc, H1 2020

Female Sexual Dysfunction – Pipeline by Better Life Pharmaceuticals Inc, H1 2020

Female Sexual Dysfunction – Pipeline by Callitas Therapeutics Inc, H1 2020

Female Sexual Dysfunction – Pipeline by Can-Fite BioPharma Ltd, H1 2020

Female Sexual Dysfunction – Pipeline by Dare Bioscience Inc, H1 2020

Female Sexual Dysfunction – Pipeline by Emotional Brain BV, H1 2020

Female Sexual Dysfunction – Pipeline by EndoCeutics Inc, H1 2020

Female Sexual Dysfunction – Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2020

Female Sexual Dysfunction – Pipeline by H. Lundbeck AS, H1 2020

Female Sexual Dysfunction – Pipeline by Harrow Health Inc, H1 2020

Female Sexual Dysfunction – Pipeline by Ivix Ltd, H1 2020

Female Sexual Dysfunction – Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2020

Female Sexual Dysfunction – Pipeline by M et P Pharma AG, H1 2020

Female Sexual Dysfunction – Pipeline by Re-Pharm Ltd, H1 2020

Female Sexual Dysfunction – Pipeline by S1 Biopharma Inc, H1 2020

Female Sexual Dysfunction – Pipeline by TherapeuticsMD Inc, H1 2020

Female Sexual Dysfunction – Dormant Projects, H1 2020

Female Sexual Dysfunction – Dormant Projects, H1 2020 (Contd..1), H1 2020

Female Sexual Dysfunction – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Female Sexual Dysfunction, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports